Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma

Rajesh K. Shetty, Benjamin H. Adams, Han W. Tun, Brandon R. Runyan, David M. Menke, Daniel F. Broderick

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The clinical efficacy of rituximab therapy in systemic mucosa-associated lymphoid tissue (MALT) lymphoma with both periocular and intraocular involvement is described. Ophthalmic examination and radiologic imaging demonstrated tumor with bilateral periorbital, lacrimal, and subconjunctival infiltration, a pseudohypopyon in one eye, and extensive systemic lymph node involvement. Lymph node biopsy confirmed the pathologic findings of a low-grade MALT lymphoma. The patient had a complete remission within 3 months of starting rituximab therapy. A recurrence 6 months later remitted with a second round of rituximab therapy and the patient remained tumor-free at 1 year.

Original languageEnglish (US)
Pages (from-to)110-112
Number of pages3
JournalOcular Immunology and Inflammation
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2010

Keywords

  • Glaucoma
  • Lymphoma
  • Rituximab
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma'. Together they form a unique fingerprint.

  • Cite this